US 12,214,036 B2
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
Jonathan Rios-Doria, Wallingford, PA (US); and Holly K. Koblish, Exton, PA (US)
Assigned to Incyte Corporation, Wilmington, DE (US)
Filed by Incyte Corporation, Wilmington, DE (US)
Filed on Mar. 5, 2021, as Appl. No. 17/193,631.
Claims priority of provisional application 62/986,482, filed on Mar. 6, 2020.
Prior Publication US 2021/0275666 A1, Sep. 9, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 31/53 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC A61K 39/3955 (2013.01) [A61K 31/53 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01)] 17 Claims
 
1. A method of treating cancer in a patient, comprising administering to said patient:
(i) Compound 1, having the structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof; and
(ii) an antibody, or an antigen-binding fragment thereof, that binds to human PD-1, wherein the antibody, or the antigen-binding fragment thereof comprises a variable heavy (VH) domain and a variable light (VL) domain, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:4 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:5;
wherein the cancer is colorectal cancer.